Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥170.9 million and basic earnings per share back in the red at ¥0.21 loss per share.
Short term traders see another biotech setback. Longer term investors will focus on the bigger question that now hangs over Junshi: whether a loss making quarter interrupts the path implied by forecasts that point to earnings improvement and potential profitability over the next few years.
Love the long term earnings potential at Shanghai Junshi Biosciences but concerned about another loss making quarter and share price pressure this month? Check out the list of solid balance sheet and fundamentals stocks (203 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): ¥817.2 million vs. ¥637.5 million (top line increase of about 28%)
- Net Loss (Q3 2026 vs Q3 2025): ¥170.9 million loss vs. ¥183.0 million loss (slightly narrower quarterly loss)
- Basic EPS (Q3 2026 vs Q3 2025): ¥0.21 loss per share vs. ¥0.18 loss per share (per share loss widened)
- Trailing 12 Month Revenue (Q3 2026 vs Q3 2025): ¥3.21b vs. ¥2.33b (higher revenue base over the last year)
Prefer clean charts over another wall of earnings tables and footnotes? See Shanghai Junshi Biosciences' full visual financial picture, including a clear view of its path from recurring losses toward potential profitability, in the company report for Shanghai Junshi Biosciences.
Shanghai Junshi Biosciences: What Still Appeals To Bulls
Shanghai Junshi Biosciences gives growth optimists something to work with. Revenue of ¥817.2 million in Q3 2026, alongside trailing 12 month sales of ¥3.21b, points to a larger commercial base than a year ago. Recent NMPA label expansion for toripalimab in resectable NSCLC and acceptance of the subcutaneous toripalimab sNDA support the idea of a broadening oncology franchise. New phase 3 starts for JS203 and JS207 plus JS007 keep the multi asset story alive, which aligns with investors who focus on pipeline breadth and ongoing product launches.
Shanghai Junshi Biosciences: Where The Bear Story Bites
The bear case leans on profitability and execution risk, and the latest quarter does not really soften that view. Shanghai Junshi Biosciences posted a net loss of ¥170.9 million and a wider ¥0.21 loss per share despite higher sales. That tension between revenue and earnings keeps questions around spending discipline front and center. A share price that has fallen about 21% over 30 days suggests traders remain cautious. A crowded trial calendar and expanding toripalimab label both require sustained funding, which keeps concerns about ongoing cash usage and pipeline risk very much alive.
Losses, a packed trial schedule and a share price under pressure all raise the same question for Shanghai Junshi Biosciences: Can the balance sheet really fund this plan without painful dilution or liquidity stress? Verify the runway, cash position and debt profile in the financial health analysis of Shanghai Junshi Biosciences stock
Hunt Quiet Disconnects In Earnings
Shanghai Junshi Biosciences reminds investors that revenue gains can appear together with quarterly losses. The real opportunity sits in finding stocks that could be undervalued before the market closes the gap.
- Company 1 - 24% below our estimate - uses cable project backlogs and high capacity utilization to secure long dated grid and energy transition contracts.
- Company 2 - 25% below our estimate - advances copper projects that move from delayed pre-stripping toward higher output as permits and development work progress.
- Company 3 - 33% below our estimate - shifts toward seeds, sustainable inputs and digital farming tools as growers adopt integrated platforms.
Three companies from the same screener. Open every one of the 197 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com